NeuroScientific Biopharmaceuticals (ASX:NSB) confirmed that the clinical preparation for the first patient to receive the first of four treatments, under the special access program in fistulising Crohn's disease, began, according to a Friday ASX filing.
It said it had progressed the proposed acquisition of the StemSmart patented stem cell technology from Isopogen WA.
The treatments will begin on or around June 2, with evaluation to be conducted over eight to ten weeks. Fistulas are one of the most severe complications associated with Crohn's disease and are challenging to treat, the filing noted.
The first patient, along with another three patients, will together form the first cohort of patients tested under the program.
Early indications from a phase two trial in refractory Crohn's disease suggest that StemSmart technology is efficacious and safe, per the filing. If the program is successful, it will progress to a phase 1/2 clinical trial.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。